The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, de Bruin G, Kisselev A, Overkleeft H, Driessen C. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemother Pharmacol 2015; 76:383-96.
Jun 23, 2015
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Jun 23, 2015
Cancer Chemother Pharmacol 2015; 76:383-96
Kraus Johannes, Kraus Marianne, Liu Nora, Besse Lenka, Bader Jürgen, Geurink Paul P, de Bruin Gerjan, Kisselev Alexei F, Overkleeft Herman, Driessen Christoph
more